Cargando…

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction

BACKGROUND: Biomarkers may help us to unravel differences in the underlying pathophysiology between heart failure (HF) patients with a reduced ejection fraction (HFrEF) and a preserved ejection fraction (HFpEF). Therefore, we compared biomarker profiles to characterize pathophysiological differences...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tromp, Jasper, Khan, Mohsin A. F., Klip, IJsbrand T., Meyer, Sven, de Boer, Rudolf A., Jaarsma, Tiny, Hillege, Hans, van Veldhuisen, Dirk J., van der Meer, Peter, Voors, Adriaan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532986/ https://www.ncbi.nlm.nih.gov/pubmed/28360225 http://dx.doi.org/10.1161/JAHA.116.003989

Ejemplares similares

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
por: de Boer, Rudolf A, et al.
Publicado: (2011)

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides
por: Meijers, W. C., et al.
Publicado: (2016)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction
por: Schroten, Nicolas F., et al.
Publicado: (2015)

Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations
por: Vegter, Eline L., et al.
Publicado: (2017)

Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction
por: Gehlken, Carolin, et al.
Publicado: (2021)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Renal dysfunction is associated with shorter telomere length in heart failure
por: Wong, Liza S. M., et al.
Publicado: (2009)

Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
por: Klaassen, Sebastiaan HC, et al.
Publicado: (2020)

Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population
por: Chia, Yook Chin, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis
por: van den Berg, Maarten P, et al.
Publicado: (2019)

Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates
por: Grote Beverborg, Niels, et al.
Publicado: (2015)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
por: Nauta, Jan F., et al.
Publicado: (2019)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

N‐terminal pro‐B‐type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure
por: Tromp, Jasper, et al.
Publicado: (2018)

Current and novel renal biomarkers in heart failure
por: Damman, Kevin, et al.
Publicado: (2011)

Epicardial fat in heart failure patients with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2018)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction
por: Curran, Fraser M., et al.
Publicado: (2021)

Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
por: Nauta, J. F., et al.
Publicado: (2021)

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure
por: Linssen, G. C. M., et al.
Publicado: (2018)

Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
por: Wintrich, Jan, et al.
Publicado: (2020)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
por: Withaar, Coenraad, et al.
Publicado: (2020)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)

Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study
por: Binnenmars, S. Heleen, et al.
Publicado: (2022)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
por: Hoes, Martijn F., et al.
Publicado: (2019)

A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts
por: Chen, Yuntao, et al.
Publicado: (2021)

Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
por: Markousis-Mavrogenis, George, et al.
Publicado: (2021)

Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis
por: Jin, Xuanyi, et al.
Publicado: (2022)

Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence
por: Bracun, Valentina, et al.
Publicado: (2022)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
por: Tay, Wan Ting, et al.
Publicado: (2021)

The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pv5ig8nd9la4uql3en8otocuqp